Aston Sci gets US FDA nod to begin phase 2 trial of therapeutic cancer vaccine AST-301 in patients with HER2 1+/2+ breast cancer

Aston Sci. Inc., a clinical stage biopharmaceutical company specializing in clinical development of therapeutic cancer vaccines, announced that it has obtained IND approval from the US Food and Drug Administration (FDA) for phase 2 clinical trial of its main product, AST-301(HER2-hICD vaccine). Accordingly, CornerStone-001(NCT05163223), a phase 2 clinical trial of AST-301(pNGVL3-hICD) for treating HER2- 1+/2+ breast cancer, is anticipated to proceed smoothly in the US following Australia and the Taiwan region. Aston Sci. has already confirmed the safety/tolerability, immunogenicity, and survival rate of AST-301 by presenting the phase 1 results(PI: Mary L. (Nora) Disis, M.D., University of Washington) including a follow-up study of more than 10 years on breast cancer patients with HER2 expression, at the American Society of Clinical Oncology (ASCO) last year. The therapeutic cancer vaccine is expected to play a major role in preventing cancer recurrence after surgery and treating advanced cancer as it causes few adverse reactions and maintains long-term immunological memory compared to existing anticancer treatments. The phase 2 clinical trial of AST-301 adopts a placebo-controlled randomized design and is a multiregional clinical trial(MRCT) in which AST-301 (study drug) is administered in combination with standard treatments, such as Capecitabine or Pembrolizumab, in patients with a high risk of recurrence following a curative surgery. A total of 146 patients would be enrolled in the study and get 3 immunizations (every 3 weeks, intradermal injection), fully aligning with a standard treatment schedule, followed by a booster immunization based on the investigator

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!